Patents by Inventor Tatiana I. NOVOBRANTSEVA

Tatiana I. NOVOBRANTSEVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VSIG4 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF
    Publication number: 20230348603
    Abstract: The present invention is based, in part, on the discovery of anti-VSIG4 composition (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-VSIG4 compositions for therapeutic, diagnostic, prognostic, and screening purposes.
    Type: Application
    Filed: May 28, 2021
    Publication date: November 2, 2023
    Inventors: Tatiana I. Novobrantseva, Igor Feldman, Stephen L. Sazinsky, Elizabeth Culyba, Phuong Anh Nguyen, Maja Razlog
  • ANTI-PSGL-1 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFALMMATORY PHENOTYPES AND USES THEREOF
    Publication number: 20220396632
    Abstract: The present invention is based, in part, on the discovery of anti-PSGL-1 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof) that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-PSGL-1 compositions for therapeutic, diagnostic, prognostic, and screening purposes.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 15, 2022
    Inventors: Tatiana I. Novobrantseva, Igor Feldman, Stephen L. Sazinsky, Joseph A. Wahle, Brian O'Nuallain, Ryan Phennicie
  • ANTI-SIGLEC-9 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF
    Publication number: 20220396627
    Abstract: The present invention is based, in part, on the discovery of anti-SIGLEC-9 composition (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-SIGLEC-9 compositions for therapeutic, diagnostic, prognostic, and screening purposes.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 15, 2022
    Inventors: Tatiana I. Novobrantseva, Igor Feldman, Stephen L. Sazinsky, Joseph A. Wahle, Ryan Phennicie
  • ANTI-LRRC25 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF
    Publication number: 20220363752
    Abstract: The present invention is based, in part, on the discovery of anti-LRRC25 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate inflammatory phenotypes of myeloid cells, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-LRRC25 compositions for therapeutic, diagnostic, prognostic, and screening purposes.
    Type: Application
    Filed: June 17, 2020
    Publication date: November 17, 2022
    Inventors: Tatiana I. Novobrantseva, lgor Feldman, Stephen L. Sazinsky, Joseph A. Wahle, Brian O'Nuallain
  • ANTI-CD53 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF
    Publication number: 20220251233
    Abstract: The present invention is based, in part, on the discovery of anti-CD53 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof), that regulate inflammatory phenotypes of myeloid cells, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-CD53 compositions for therapeutic, diagnostic, prognostic, and screening purposes.
    Type: Application
    Filed: June 17, 2020
    Publication date: August 11, 2022
    Inventors: Tatiana I. Novobrantseva, Igor Feldman, Stephen L. Sazinsky, Joseph A. Wahle
  • OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND USES THEREOF
    Publication number: 20210317461
    Abstract: The present invention is based, in part, on providing oligonucleotide compositions for targeting CCR2, CSF1R, and/or both CCR2 and CSF1R, as well as methods of use thereof, such as to modulate myeloid-derived cell inflammatory phenotypes and immune responses that are mediated by such cells.
    Type: Application
    Filed: August 9, 2019
    Publication date: October 14, 2021
    Inventors: Tatiana I. Novobrantseva, Kevin Kauffman
  • ASSAYS FOR THE DETECTION OF AAV NEUTRALIZING ANTIBODIES
    Publication number: 20210285931
    Abstract: The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 16, 2021
    Inventors: Tatiana I. Novobrantseva, Dinah Wen-Yee Sah
  • COMPOSITIONS AND METHODS FOR MODULATING MONOCYTE AND MACROPHAGE INFLAMMATORY PHENOTYPES AND IMMUNOTHERAPY USES THEREOF
    Publication number: 20210189342
    Abstract: The present invention is based, in part, on the identification of compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof.
    Type: Application
    Filed: June 28, 2019
    Publication date: June 24, 2021
    Inventors: Tatiana I. Novobrantseva, Igor Feldman
  • Assays for the detection of AAV neutralizing antibodies
    Patent number: 10983110
    Abstract: The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 20, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Tatiana I. Novobrantseva, Dinah Wen-Yee Sah
  • ASSAYS FOR THE DETECTION OF AAV NEUTRALIZING ANTIBODIES
    Publication number: 20180356394
    Abstract: The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Applicant: Voyager Therapeutics, Inc.
    Inventors: Tatiana I. NOVOBRANTSEVA, Dinah Wen-Yee SAH